F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients
Benzinga2021-08-12
- F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.
- The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
- FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
- In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.
- F-Star ended the quarter with cash and cash equivalents of $81.6 million.
- Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.
免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。